Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 456

1.

Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.

Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, Woo KS, Sanderson JE.

Am J Kidney Dis. 2004 May;43(5):801-8.

PMID:
15112170
2.

N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.

Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.

Am Heart J. 2009 Mar;157(3):576-83. doi: 10.1016/j.ahj.2008.11.010. Epub 2009 Feb 6.

PMID:
19249432
3.

Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.

Ramesh N, Pillai RK, Abraham T, Padmaja NP, Hameed S, Vijayaraghavan G.

J Assoc Physicians India. 2006 Jun;54:449-52.

PMID:
16909692
4.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012
5.

Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.

Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ.

Am Heart J. 2006 May;151(5):1032.e9-12.

PMID:
16644332
6.

Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV.

Circulation. 2004 Nov 2;110(18):2837-42. Epub 2004 Oct 18. Erratum in: Circulation. 2005 Jan 25;111(3):379. Iacovis, Panagiotis [corrected to Iokovis,Panagiotis].

7.

N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.

Duong MH, MacKenzie TA, Malenka DJ.

Catheter Cardiovasc Interv. 2005 Apr;64(4):471-9. Review.

PMID:
15789388
8.

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.

Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK.

Catheter Cardiovasc Interv. 2002 Nov;57(3):279-83.

PMID:
12410497
9.

[Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography].

El Mahmoud R, Le Feuvre C, Le Quan Sang KH, Helft G, Beygui F, Batisse JP, Metzger JP.

Arch Mal Coeur Vaiss. 2003 Dec;96(12):1157-61. French.

PMID:
15248440
10.

Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.

Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA.

Clin Cardiol. 2004 Nov;27(11):607-10.

11.

Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.

Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F.

Am J Cardiol. 2010 Feb 1;105(3):288-92. doi: 10.1016/j.amjcard.2009.09.026. Epub 2009 Dec 21.

PMID:
20102936
12.

Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.

Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK.

Am J Kidney Dis. 2009 Oct;54(4):602-9. doi: 10.1053/j.ajkd.2009.03.024. Epub 2009 Jun 17.

PMID:
19535188
13.

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.

Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V.

Eur Heart J. 2004 Feb;25(3):212-8. Review.

PMID:
14972421
14.

Acetylcysteine and contrast agent-associated nephrotoxicity.

Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B.

J Am Coll Cardiol. 2002 Jul 17;40(2):298-303.

15.

Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.

MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK.

Catheter Cardiovasc Interv. 2003 Dec;60(4):458-61.

PMID:
14624421
16.

Post-coronarography application of continuous veno-venous hemofiltration in the prevention of contrast nephropathy in patients with complex multisystem deficiency.

La Manna G, Pancaldi L, Dalmastri V, Cuna V, Capecchi A, Comai G, Persici E, Bacchi G, Cianciolo G, Lombardi A, Marrozzini C, Colì L, Stefoni S.

In Vivo. 2008 Jan-Feb;22(1):123-9.

17.
19.

Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).

Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, Lee JY, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Suh J, Cho YH, Lee NH, Cheong SS, Yoo SY, Lee BK, Lee SG, Hyon MS, Shin WY, Lee SW, Jang JS, Park SJ.

Am J Cardiol. 2011 May 15;107(10):1447-52. doi: 10.1016/j.amjcard.2011.01.019. Epub 2011 Mar 17.

PMID:
21420063
20.

Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Spargias K, Adreanides E, Demerouti E, Gkouziouta A, Manginas A, Pavlides G, Voudris V, Cokkinos DV.

Circulation. 2009 Nov 3;120(18):1793-9. doi: 10.1161/CIRCULATIONAHA.109.863159. Epub 2009 Oct 19.

Supplemental Content

Support Center